Pages that link to "Q84513586"

The following pages link to Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma (Q84513586):

Displaying 26 items.

• CD133: to be or not to be, is this the real question? (Q24615405) (← links)
• Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival (Q26853543) (← links)
• Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch. (Q33806379) (← links)
• Clinical implications of cancer stem cell biology in hepatocellular carcinoma (Q34357073) (← links)
• Prognostic value of CD133 expression in stage I lung adenocarcinomas (Q34467221) (← links)
• Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma (Q35745018) (← links)
• DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma (Q36740566) (← links)
• Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma (Q37095091) (← links)
• CD133 expression associated with poor prognosis in ovarian cancer (Q37373712) (← links)
• Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer (Q37468314) (← links)
• Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells (Q37679158) (← links)
• Biology and clinical implications of CD133(+) liver cancer stem cells. (Q38045627) (← links)
• Cervical cancer stem cells: opportunities and challenges (Q38309029) (← links)
• Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. (Q38817435) (← links)
• CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality? (Q38922806) (← links)
• CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide (Q39014873) (← links)
• CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope (Q39243687) (← links)
• Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA). (Q40648635) (← links)
• CD133 expression: a potential prognostic marker for non-small cell lung cancers (Q43533886) (← links)
• Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients (Q47112528) (← links)
• Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma (Q47627396) (← links)
• CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis (Q50053330) (← links)
• Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. (Q53526112) (← links)
• Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer (Q58572653) (← links)
• Recycling endosomal CD133 functions as an inhibitor of autophagy at the pericentrosomal region (Q64258075) (← links)
• Branched-chain amino acid-enriched nutrients stimulate antioxidant DNA repair in a rat model of liver injury induced by carbon tetrachloride (Q87424365) (← links)